Visolis General Information
Visolis has successfully scaled its technology to ton-level manufacturing, delivered on-spec products to early customers, secured multi-million-dollar joint development agreements, achieved multi-millions in annual revenue, and is preparing to launch its first large-scale commercial facility in 2025—a 40X scale-up from current operations. The company’s platform produces sustainable aviation fuel (SAF), synthetic rubber precursors like bio-isoprene, non-toxic solvents, synthetic latexes, and other specialty/commodity chemicals with lower cost and carbon footprint than traditional processes. Visolis’ SAF offers higher energy density than many alternatives. Its process uses waste biomass or CO₂ as feedstock via engineered microbes followed by chemical catalysis for efficient production at scale. The company recently received a $2.25M U.S. Department of Defense award for domestic manufacturing expansion. No clinical results are relevant.
Contact Information
Drug Pipeline
No pipeline data available
Key Partnerships
Ginkgo Bioworks
Visolis Funding
No funding data available
Gosset